Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (LT5623) 5-ARYL-4-(5-SUBSTITUTED 2,4-DIHYDROXYFENIL)-1,2,3-THIADIAZOLES AS INHIBITORS OF HSP90 CHAPERONE AND THE INTERMEDIATES FOR PRODUCTION THEREOF

Office : Lithuania
Application Number: 2008035 Application Date: 30.04.2008
Publication Number: 5623 Publication Date: 25.11.2009
Grant Number: 5623 Grant Date: 25.01.2010
Publication Kind : B
IPC:
C07D 285/00
A61K 31/433
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
285
Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/-C07D283/183
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
41
having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
433
Thiadiazoles
CPC:
C07D 285/06
Applicants: BIOTECHNOLOGIJOS INST
Inventors: MATULIS DAUMANTAS
CIKOTIENE INGA
KAZLAUSKAS EGIDIJUS
MATULIENE JURGITA
Priority Data: 2008035 30.04.2008 LT
Title: (EN) 5-ARYL-4-(5-SUBSTITUTED 2,4-DIHYDROXYFENIL)-1,2,3-THIADIAZOLES AS INHIBITORS OF HSP90 CHAPERONE AND THE INTERMEDIATES FOR PRODUCTION THEREOF
(LT) 5-ARIL-4-(5-PAKEISTIEJI 2,4-DIHIDROKSIFENIL)-1,2,3-TIADIAZOLAI KAIP HSP90 ŠAPERONO SLOPIKLIAI IR TARPINIAI JUNGINIAI JIEMS GAUTI
Abstract:
(EN) Ivention is related to novel compounds - 5-aryl-4-(5-substituted 2,4-dihydroxyphenyl)-1,2,3-thiadiazoles with general formula (I). The compounds can be used in biomedicine as active ingredients in pharmaceutical formulations, because they inhibit Hsp90 chaperone which participate in cancer progression. This invention is also related to new intermediate compounds which are used for the synthesis of thiadiazoles of formula (I).@
(LT) Išradimas yra susijčs su naujais junginiais - 5-aril-4-(5-pakeistais 2,4-dihidroksifenil)-1,2,3-tiazolidais, kurių bendra formulė (I). Šie junginiai gali būti naudojami biomedicinoje kaip vaistinių preparatų veikliosios medžiagos, nes pasižymi vėžioprogresavime dalyvaujančio Hsp90 šaperono slopinimu. Taip pat išradimas suisjęs su naujais tarpiniais junginiais, reikalingais bendrosios formulės (I) tiadiazolų sintezei.